2024
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Longlax S, Koster K, Kamat A, Lozano M, Lerner S, Hannigan R, Nishiguchi T, Abhimanyu, Sheikh D, Ladki M, Portillo A, Koirala A, Patel T, Spieler Z, Benjamin A, Lebedev M, Ofili T, Hutchison R, Udeani G, Opperman L, Neal G, Mandalakas A, Netea M, Arditi M, Avalos P, Grimm S, Coarfa C, Cirillo J, DiNardo A. BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infectious Diseases 2024, 12: ofaf007. PMID: 39872813, PMCID: PMC11770274, DOI: 10.1093/ofid/ofaf007.Peer-Reviewed Original ResearchVaccine immunityDNA methylation changesBCG-induced trained immunityClinical trialsBCG vaccinationPlacebo-controlled clinical trialStudy enrollmentAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionCovid-19 specific vaccineMethylation changesCoronavirus 2 infectionCOVID-19 vaccine immunitySymptomatic COVID-19Secondary analysisSARS-CoV-2 antigensInnate immune responseDouble-blindPlacebo armBCG TiceTrained immunitySevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Coronavirus immunityRespiratory syndrome coronavirus 2
2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj G, Vinayak S, Khaki A, Sun T, Kuderer N, Aboulafia D, Acoba J, Awosika J, Bakouny Z, Balmaceda N, Bao T, Bashir B, Berg S, Bilen M, Bindal P, Blau S, Bodin B, Borno H, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman L, Flora D, Friese C, Galsky M, Gonzalez C, Grivas P, Gupta S, Haynam M, Heilman H, Hershman D, Hwang C, Jani C, Jhawar S, Joshi M, Kaklamani V, Klein E, Knox N, Koshkin V, Kulkarni A, Kwon D, Labaki C, Lammers P, Lathrop K, Lewis M, Li X, de Lima Lopes G, Lyman G, Makower D, Mansoor A, Markham M, Mashru S, McKay R, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen R, Nonato T, O'Connor T, Panagiotou O, Park K, Patel J, Patel K, Peppercorn J, Polimera H, Puc M, Rao Y, Razavi P, Reid S, Riess J, Rivera D, Robson M, Rose S, Russ A, Schapira L, Shah P, Shanahan M, Shapiro L, Smits M, Stover D, Streckfuss M, Tachiki L, Thompson M, Tolaney S, Weissmann L, Wilson G, Wotman M, Wulff-Burchfield E, Mishra S, French B, Warner J, Lustberg M, Accordino M, Shah D. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife 2023, 12: e82618. PMID: 37846664, PMCID: PMC10637772, DOI: 10.7554/elife.82618.Peer-Reviewed Original ResearchConceptsCOVID-19 severityWorse COVID-19 outcomesCOVID-19 outcomesBreast cancerCause mortalityCohort studyAcute respiratory syndrome coronavirus 2 infectionCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionRegistry-based retrospective cohort studyHistory of BCIntensive care unit admissionNon-Hispanic white patientsSyndrome coronavirus 2 infectionWorse ECOG performance statusMultivariable ordinal logistic regression modelsCare unit admissionCoronavirus 2 infectionECOG performance statusRetrospective cohort studyPacific Islander patientsCoronavirus disease 2019American Cancer SocietyLogistic regression modelsResearch grant supportCharacterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Zendt M, Carrillo F, Kelly S, Saturday T, DeGrange M, Ginigeme A, Wu L, Callier V, Ortega-Villa A, Faust M, Chang-Rabley E, Bugal K, Kenney H, Khil P, Youn J, Osei G, Regmi P, Anderson V, Bosticardo M, Daub J, DiMaggio T, Kreuzburg S, Pala F, Pfister J, Treat J, Ulrick J, Karkanitsa M, Kalish H, Kuhns D, Priel D, Fink D, Tsang J, Sparks R, Uzel G, Waldman M, Zerbe C, Delmonte O, Bergerson J, Das S, Freeman A, Lionakis M, Sadtler K, van Doremalen N, Munster V, Notarangelo L, Holland S, Ricotta E. Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies. Science Advances 2023, 9: eadh3150. PMID: 37824621, PMCID: PMC10569702, DOI: 10.1126/sciadv.adh3150.Peer-Reviewed Original ResearchConceptsHealthy volunteersIgG levelsDose of coronavirus diseaseImmune response to COVID-19 vaccinationResponse to COVID-19 vaccinationAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionMessenger RNA-based vaccinesMedian IgG levelsOrgan transplant populationCoronavirus 2 infectionRNA-based vaccinesImmunomodulating treatmentTransplant populationDose 2Dose 3Prospective cohortCoronavirus diseaseDoseCOVID-19 vaccineOmicron BABivalent vaccineImmunoglobulin GVaccineIgGIntegrated Immunopeptidomics and Proteomics Study of SARS-CoV-2–Infected Calu-3 Cells Reveals Dynamic Changes in Allele-specific HLA Abundance and Antigen Presentation
Chen R, Fulton K, Tran A, Duque D, Kovalchik K, Caron E, Twine S, Li J. Integrated Immunopeptidomics and Proteomics Study of SARS-CoV-2–Infected Calu-3 Cells Reveals Dynamic Changes in Allele-specific HLA Abundance and Antigen Presentation. Molecular & Cellular Proteomics 2023, 22: 100645. PMID: 37709257, PMCID: PMC10580047, DOI: 10.1016/j.mcpro.2023.100645.Peer-Reviewed Original ResearchSARS-CoV-2 infectionHuman leukocyte antigenAdaptive immune systemHLA allelesAntigen presentationAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionImmune systemSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) casesHost proteome changesCoronavirus 2 infectionCertain HLA allelesToll-like receptorsDifferent HLA allelesCoronavirus disease 2019Calu-3 cellsHost cellsLeukocyte antigenViral antigensDisease 2019Viral infectionDevelopment of therapeuticsInfectionClass IPharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
Wei J, Patil A, Collings C, Alfajaro M, Liang Y, Cai W, Strine M, Filler R, DeWeirdt P, Hanna R, Menasche B, Ökten A, Peña-Hernández M, Klein J, McNamara A, Rosales R, McGovern B, Luis Rodriguez M, García-Sastre A, White K, Qin Y, Doench J, Yan Q, Iwasaki A, Zwaka T, Qi J, Kadoch C, Wilen C. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. Nature Genetics 2023, 55: 471-483. PMID: 36894709, PMCID: PMC10011139, DOI: 10.1038/s41588-023-01307-z.Peer-Reviewed Original ResearchConceptsMSWI/SNF complexesAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionHost-directed therapeutic targetSyndrome coronavirus 2 infectionSARS-CoV-2 infectionSWItch/Sucrose Non-Fermentable (SWI/SNF) chromatinSARS-CoV-2 susceptibilityNon-fermentable (SWI/SNF) chromatinCoronavirus 2 infectionEnzyme 2 (ACE2) expressionSARS-CoV-2 variantsHuman cell typesPrimary human cell typesAirway epithelial cellsDrug-resistant variantsNew drug targetsChromatin accessibilitySNF complexACE2 locusACE2 expressionFactor complexHost determinantsTherapeutic targetConfer resistanceHuman Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, Horberg M, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clinical Infectious Diseases 2023, 76: 1727-1734. PMID: 36861341, PMCID: PMC10209434, DOI: 10.1093/cid/ciad084.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAdjusted risk ratioCOVID-19 hospitalizationMechanical ventilationTenofovir useHIV statusAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere coronavirus disease 2019 (COVID-19) outcomesSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) outcomesHuman immunodeficiency virus statusCohort of PWHCD4 cell countCharlson Comorbidity IndexCoronavirus 2 infectionHIV RNA levelsUnited States cohortBody mass indexCOVID-19 severityCOVID-19 vaccine availabilityReal-world analysisTenofovir exposureComorbidity indexMass indexPopulation-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic
Pérez-Then E, Miric M, Qian H, Chen Y, Wang Y, Vallejo V, Quezada W, Flaquer M, Olivo J, Castillo J, García N, Calderón K, Cueto S, Veras B, Russo M, Jiménez I, Guzmán S, Garabito L, Cueto E, Colombo F, Taveras D, Torres D, Baez J, Yunen J, Koenig E, Pérez E, López O, Medina F, Wang X, Shao Y, Vermund S, Díaz G, Severino F, Acevedo A, Luciano J, Cuello J, Acevedo I, Espinál M, Martínez C, Díaz D, Espinál D, Almonte D, Rodríguez J, Rosa J, Reyes J, Fernández J, De Jesús Marte Mercado M, De Los Santos Carmona R, Liriano R, Heyliger A, Mejía A, Turbis A, Aquino C, José E, Del Rosario Y, Rosario C, Hermón J, Colón A, Flores A, Díaz C, Rodríguez D, Estrella J, Colón J, Reyes J, Gil L, Abbott M, de Mota M, Polanco N, Jiménez I, Santana R, Herrera S, Castellanos A, Germosén A, Fajardo F, Mercedes K, Méndez M, F S, Sánchez T, Payano Y, Gómez Y, Mejía Y, Sánchez D, Infante H, Grullón M, Lemos Y, Carpio P, Pineda C, Núñez M, Espiritusanto D, Álvarez G, Nina G, Cabrera K, Guerrero R, Mejía B, Nicolás K, Guante M, Lebrón M, Bidó M, Monción M, Brito E, Rosado S, de apoyo P, de Sosa A, Pimentel B, Feliciano D, de los Santos L, Morillo M, Mateo P, de la Cruz R, de los Ángeles García M, Tavárez Y, Luna R, Castillo Y, Ulloa E, Pérez E. Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic. Open Forum Infectious Diseases 2023, 10: ofad075. PMID: 36998630, PMCID: PMC10043129, DOI: 10.1093/ofid/ofad075.Peer-Reviewed Original ResearchSymptomatic SARS-CoV-2 infectionTest-negative case-control studyCOVID-19-related hospitalizationSARS-CoV-2 infectionCase-control studyCOVID-19 vaccineFull vaccinationAssisted ventilationPartial vaccinationLower oddsAcute respiratory syndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccination programsInactivated COVID-19 vaccineNegative case-control studySyndrome coronavirus 2 infectionPositive polymerase chain reaction testCOVID-19-related symptomsNationwide vaccination campaignPCR-positive participantsCoronavirus 2 infectionReal-world effectivenessPolymerase chain reaction testPopulation-level effectivenessSARS-CoV-2Chain reaction testPalliative Care in a Pandemic: A Multicenter Cohort of Critically Ill Patients with Coronavirus Disease 2019
Kodadek L, Moore M, Miller S, Schneider E, Ahuja V, Maerz L, Davis K. Palliative Care in a Pandemic: A Multicenter Cohort of Critically Ill Patients with Coronavirus Disease 2019. Surgical Infections 2023, 24: 190-198. PMID: 36757283, PMCID: PMC10081705, DOI: 10.1089/sur.2022.377.Peer-Reviewed Original ResearchConceptsIntensive care unitPalliative careIll patientsCoronavirus disease 2019Life careClinical characteristicsMechanical ventilationDisease 2019Acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus 2 infectionPalliative care consultationPalliative care servicesCOVID-19Outcomes of interestHospital lengthAdult patientsComorbid diseasesDisease courseMulticenter cohortCare unitCare consultationsVaccination dataPatientsBooster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study
Wan J, Cazer C, Clarkberg M, Henderson S, Lee S, Meredith G, Osman M, Shmoys D, Frazier P. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLOS Medicine 2023, 20: e1004153. PMID: 36626376, PMCID: PMC9876273, DOI: 10.1371/journal.pmed.1004153.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionInitial vaccination seriesPositive SARS-CoV-2 PCR testSARS-CoV-2 PCR testVaccination seriesBooster doseBooster vaccinationCohort studyStudy periodYoung adultsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSevere coronavirus disease 2019Polymerase chain reaction testingCoronavirus 2 infectionRetrospective cohort studyPCR testMultivariable Poisson regressionSARS-CoV-2 variantsStatistical analysis planCoronavirus disease 2019Active surveillance approachSARS-CoV-2World Health Organization
2022
Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group
Spatz E, Gottlieb M, Wisk L, Anderson J, Chang A, Gentile N, Hill M, Huebinger R, Idris A, Kinsman J, Koo K, Li S, McDonald S, Plumb I, Rodriguez R, Saydah S, Slovis B, Stephens K, Unger E, Wang R, Yu H, Hota B, Elmore J, Weinstein R, Venkatesh A. Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group. Clinical Infectious Diseases 2022, 76: 1559-1566. PMID: 36573005, PMCID: PMC11361781, DOI: 10.1093/cid/ciac966.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 symptomsSARS-CoV-2 infectionPost-infectious syndromesProspective cohort studyCohort studyCOVID groupAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 test resultsSyndrome coronavirus 2 infectionEar/nose/throatSevere acute respiratory syndrome coronavirus 2 testsCoronavirus 2 infectionLong-term symptomsNose/throatLong COVIDSymptomatic adultsMean ageActive symptomsSymptom profilesDrug AdministrationSociodemographic characteristicsSymptomsInfectionMonths303. Viral and bacterial infections among adults hospitalized with COVID-19, Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, 14 states, March 2020–February 2022
Melisa S, Taylor C, Patel K, Milucky J, Whitaker M, Pham H, Anglin O, Reingold A, Armistead I, Yousey-Hindes K, Anderson E, Weigel A, Reeg L, Mumm E, Ropp S, Muse A, Bushey S, Shiltz E, Sutton M, Talbot K, Price A, Havers F. 303. Viral and bacterial infections among adults hospitalized with COVID-19, Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, 14 states, March 2020–February 2022. Open Forum Infectious Diseases 2022, 9: ofac492.381. PMCID: PMC9751616, DOI: 10.1093/ofid/ofac492.381.Peer-Reviewed Original ResearchDay of admissionBacterial infectionsCoronavirus diseaseRelevant bacterial pathogensCOVID-19Acute respiratory syndrome coronavirus 2 infectionLaboratory-confirmed SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionSurveillance networkCommon respiratory isolatesRV/EVCoronavirus 2 infectionRhinovirus/enterovirusBronchoalveolar lavage fluidRespiratory syncytial virusBacterial pathogensCare molecular testingHospitalized adultsBacterial coinfectionClinical featuresClinical outcomesLavage fluidSyncytial virusWaning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variantAssociation between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of testCurrent Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes
Shi X, Li K, Mukherjee B. Current Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes. American Journal Of Epidemiology 2022, 192: 328-333. PMID: 36446573, PMCID: PMC10372864, DOI: 10.1093/aje/kwac203.Peer-Reviewed Original ResearchAntiviral Treatment of Coronavirus Disease-2019 Pneumonia
Radcliffe C, Malinis M, Azar M. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Clinics In Chest Medicine 2022, 44: 279-297. PMID: 37085220, PMCID: PMC9701636, DOI: 10.1016/j.ccm.2022.11.008.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus diseaseCoronavirus 2 infectionDirect acting antiviralsAdditional clinical trialsReal-world studyCOVID-19Acting antiviralsAntiviral treatmentTherapeutic optionsAvailable therapiesClinical trialsDisease progressionInpatient treatmentHigh riskEarly pandemicMonoclonal antibodiesDiseaseTreatmentMorbidityPandemicPneumoniaOutpatientsA MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality
Verma A, Minnier J, Wan ES, Huffman JE, Gao L, Joseph J, Ho YL, Wu WC, Cho K, Gorman BR, Rajeevan N, Pyarajan S, Garcon H, Meigs JB, Sun YV, Reaven PD, McGeary JE, Suzuki A, Gelernter J, Lynch JA, Petersen JM, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Gatsby E, Lynch KE, Bonomo RA, Freiberg M, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Huang R, Polimanti R, Chang KM, Liao KP, Tsao PS, Wilson PWF, Hung A, O’Donnell C, Gaziano JM, Hauger RL, Iyengar S, Luoh SW, Initiative T. A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1220-1229. PMID: 35771531, PMCID: PMC9746845, DOI: 10.1164/rccm.202109-2166oc.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationIdiopathic pulmonary fibrosisMillion Veteran ProgramHost Genetics InitiativeAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionGene polymorphismsSyndrome coronavirus 2 infectionCoronavirus 2 infectionConfer protective effectsCOVID-19 positivityCoronavirus disease (COVID-19) infectionElectronic health recordsMVP subjectsPneumonia eventsClinical outcomesPulmonary fibrosisCOVID-19 Host Genetics InitiativeClinical eventsSevere outcomesProtective effectSevere diseaseRs35705950Disease severityMVP participantsLRRC15 inhibits SARS-CoV-2 cellular entry in trans
Song J, Chow RD, Peña-Hernández MA, Zhang L, Loeb SA, So EY, Liang OD, Ren P, Chen S, Wilen CB, Lee S. LRRC15 inhibits SARS-CoV-2 cellular entry in trans. PLOS Biology 2022, 20: e3001805. PMID: 36228039, PMCID: PMC9595563, DOI: 10.1371/journal.pbio.3001805.Peer-Reviewed Original ResearchConceptsExpression of LRRC15Receptor-binding domainViral entryAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 cellular entrySyndrome coronavirus 2 infectionSARS-CoV-2 entrySpike-mediated entryCoronavirus 2 infectionCOVID-19 patientsCellular entry factorsSARS-CoV-2Attachment factorsACE2-negative cellsEnzyme 2Receptor angiotensinEntry factorsProtective roleLRRC15Spike proteinSame cell typeCRISPR activation screensACE2Cellular entryShort- and long-term noninvasive cardiopulmonary exercise assessment in previously hospitalised COVID-19 patients
Singh I, Joseph P. Short- and long-term noninvasive cardiopulmonary exercise assessment in previously hospitalised COVID-19 patients. European Respiratory Journal 2022, 61: 2201739. PMID: 36137592, PMCID: PMC9515479, DOI: 10.1183/13993003.01739-2022.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionNoninvasive cardiopulmonary exercise testingSyndrome coronavirus 2 infectionCoronavirus 2 infectionCardiopulmonary exercise testingCoronavirus disease 2019 (COVID-19) pandemicSARS-CoV-2Disease 2019 pandemicExercise testingGlobal healthcare systemsInterval improvementExercise assessmentAerobic capacityHealthcare systemPatientsHospitalisationWorld populationPopulationInfectionMonthsStructural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey
Fofana MO, Nery N, Ticona J, de Andrade Belitardo EMM, Victoriano R, Anjos RO, Portilho MM, de Santana MC, dos Santos LL, de Oliveira D, Cruz JS, Muenker MC, Khouri R, Wunder EA, Hitchings MDT, Johnson O, Reis MG, Ribeiro GS, Cummings DAT, Costa F, Ko AI. Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey. PLOS Medicine 2022, 19: e1004093. PMID: 36074784, PMCID: PMC9499230, DOI: 10.1371/journal.pmed.1004093.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSARS-CoV-2 infection riskUrban slumsSyndrome coronavirus 2 infectionSARS-CoV-2 seroprevalenceSARS-CoV-2 incidenceCoronavirus 2 infectionCross-sectional serosurveyMain outcome measuresUrban slum populationPresence of IgGSARS-CoV-2 spike proteinUrban slum communityCross-sectional surveyUrban slum residentsCumulative incidenceMedian ageRisk factorsOutcome measuresStudy populationHigh seroprevalenceMedian dailyPandemic waveGender distributionTenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply